2013 Archived Content

SC11 CTCs from Bench to Bed:
Streamlining from Research to Clinical Practice


4:30 Opening Remarks | Patient Rights and Legal Basis for Using Human Biopsies in Clinical Research and Diagnosis

Marek Malecki, M.D., Ph.D., Associate Professor of Genetics, Genomics, and Gene Therapy; Director, Biotechnology Program, Western University of Health Sciences

4:45 Nanopores with Electronic Readout – The Next-Next Generation Sequencing

Stuart Lindsay, Ph.D., Professor, Physics and Chemistry Director, Center for Single Molecule Biophysics, Arizona State University

DNA can be threaded through a nanopore, one base at a time, for at least tens of thousands of bases. I will outline a new reading scheme (“Recognition Tunneling”) that is capable of yielding a distinct electronic signature of each base (and 5-methyl C) with no chemical processing of any kind. This technology is currently licensed with the goal of commercial production of solid-state DNA sequencing “chips”.

5:30 Break for Dinner

5:45 Novel biomarkers and approaches in molecular profiling of circulating tumor cells and cancer stem cells for clinical diagnoses.

Marek Malecki, M.D., Ph.D., Associate Professor of Genetics, Genomics, and Gene Therapy; Director, Biotechnology Program, Western University of Health Sciences

Molecular profiling of circulating tumor cells (CTC) or disseminating tumor cells (DTC) play increasing role in refining clinical diagnoses, broadcasting prognoses, and prescribing therapies. As an introduction, I will present an overview of the biomarkers for cancer and cancer stem cells used in various diagnostic and research scenarios and methods. Moreover, I will present our data concerned with the novel nanotheragnostics for ovarian and testicular cancers, which we have recently developed to target wt and mutated gene expression products: BioTags and OncoTags, and which can discriminate between the cancer and healthy cells. I will also present our results on detecting and isolating cancer stem cells using BioTags targeting cells expressing CD133, SSEA3, 4, TRA160, 181. I will conclude with examples of clinical cases.

6:15 Overview of the Different Types of Methods to Isolate and Characterize Circulating Tumor Cells

Patrizia Paterlini Brechot, M.D., Ph.D., Professor of Cell Biology/Oncology, University Paris Descartes, Director of INSERM, Unit 807 and CSO, Rarecells

Circulating tumor cells (CTC) represent a unique tumor marker for personalized and non-invasive predictive oncology and theranostics. This presentation will discuss the different methods to isolate and characterize CTC according to their potential impact in clinical oncology and their interest in the development of CTC-related molecular theranostics.

6:45 Detect, Enumerate, and Characterize CTCs without Significant Enrichment

Nan Su, Ph.D., Senior Scientist and Group Leader, Advanced Cell Diagnostics, Inc.

This talk will discuss the current CTC technology landscape and the missing pieces as well as how to achieve CTC detection and enumeration without CTC isolation or enrichment, how to conduct molecular analysis & characterization of CTCs, and where are the gaps in clinical implementation?

7:00 Legal Aspects of IP

Pat Morrison, J.D., Ph.D., Associate, Perkins Coie

7:30 Close of Course

<<Back to Short Courses 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors

Beckman Coulter Life Sciences 

Boston Healthcare



Charles River no tagline


Cofactor Genonics


Menarini Silicon Biosystems






View All Sponsors